Why use it

Follicular lymphoma is an indolent B-cell lymphoma where immediate treatment in low-burden disease does NOT improve survival compared to observation. Correctly identifying high-burden patients (who need therapy) versus low-burden patients (who can be watched) is the central clinical decision in newly diagnosed FL. GELF criteria provide an internationally validated, standardized framework for this distinction.

About

The Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria, developed by Brice et al. in 1997, define high tumor burden in follicular lymphoma (FL) and identify patients who require immediate systemic treatment rather than a watch-and-wait approach. The criteria are based on clinical and laboratory parameters that reflect disease bulk, organ compromise, and systemic disease burden. A patient meeting ANY ONE of the GELF criteria is classified as high tumor burden and should be offered therapy. Patients who meet no GELF criteria can safely undergo active surveillance (watch and wait), which has been shown in randomized trials not to compromise overall survival compared to immediate treatment in asymptomatic, low-burden FL. The GELF criteria are endorsed by the European Society for Medical Oncology (ESMO), the British Committee for Standards in Haematology (BCSH), and the Follicular Lymphoma International Prognostic Index (FLIPI) guidelines for treatment decision-making.

When to use

At diagnosis of follicular lymphoma grade 1, 2, or 3a to determine treatment vs. observation
When reassessing a previously observed FL patient for signs of disease progression requiring therapy
To document high tumor burden criteria for insurance authorization for rituximab-based therapy
In clinical trial enrollment when GELF-defined high or low tumor burden is an eligibility criterion
Multidisciplinary lymphoma team review for treatment initiation decisions

Formula

HIGH Tumor Burden = ANY ONE of the following criteria met: 1. Involvement of ≥3 nodal sites, each ≥3 cm in diameter 2. Any nodal or extranodal tumor mass ≥7 cm in greatest dimension 3. B symptoms present (fever, night sweats, or weight loss >10% in 6 months) 4. Splenomegaly ≥16 cm by CT (craniocaudal diameter) 5. Pleural effusion or ascites attributable to lymphoma 6. Cytopenia attributable to lymphoma: Hemoglobin <10 g/dL OR Platelets <100×10⁹/L 7. Leukemic phase: >5,000 circulating lymphoma cells/μL (peripheral blood) 8. Organ compromise or compression by lymphoma (ureteral, biliary, spinal, etc.) LOW Tumor Burden = 0 criteria met → Watch and Wait is appropriate

Pearls & pitfalls

A SINGLE GELF criterion is sufficient to classify as high tumor burden and indicate therapy — no threshold number is required.
ANY nodal or extranodal mass ≥7 cm (not 6 cm) qualifies — this is a common point of confusion with the Lugano criteria.
B symptoms in FL include fever >38°C, drenching night sweats, and weight loss >10% in 6 months.
The GELF criteria were validated in patients with grade 1–3a FL — grade 3b FL is now classified and treated as diffuse large B-cell lymphoma (DLBCL).
BNLI (British National Lymphoma Investigation) criteria are similar but not identical to GELF — GELF is more widely cited internationally.
Pleural effusion or ascites due to lymphoma qualifies as a compressive/infiltrative sign — even small effusions count if due to lymphoma.
Cytopenias qualifying for GELF: Hgb <10 g/dL OR platelets <100×10⁹/L — must be attributable to lymphoma (bone marrow infiltration or hypersplenism), not other causes.
Spleen ≥16 cm by CT (craniocaudal diameter) is the GELF threshold — not simply "splenomegaly".
Watch and wait does NOT mean "ignore" — patients require regular reassessment (every 3–6 months) with clinical evaluation and repeat imaging as clinically indicated.

Next steps

High Tumor Burden (≥1 GELF criterion met): Systemic therapy indicated. Standard of care: R-CHOP, R-CVP, R-bendamustine, or obinutuzumab-based regimens depending on patient fitness and institutional protocol. Followed by rituximab maintenance (2 years). Low Tumor Burden (0 GELF criteria met): Watch and wait is safe and appropriate. No survival disadvantage vs. immediate treatment. Schedule clinical reassessment every 3–6 months. Education about symptoms requiring early return. Patient preference for treatment should be respected even in low-burden disease — discuss individual preferences.

Evidence

Brice P et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the GELF. J Clin Oncol. 1997;15(3):1110-1117. PMID:9060552. Ardeshna KM et al. (BNLI Trial) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma. Lancet. 2003;362:516-522. PMID:12932382. Follicular Lymphoma ESMO Clinical Practice Guidelines 2023.

References

Brice P et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa. J Clin Oncol. 1997;15(3):1110-1117. — link
Ardeshna KM et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma. Lancet. 2003;362(9383):516-522. — link
Dreyling M et al. ESMO Consensus Conferences: guidelines on malignant lymphoma. Part 1: Diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia. Ann Oncol. 2013;24(9):2210-2220. — link

GELF Criteria for Follicular Lymphoma

Calculator